This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
The data presented in this study are available in this article.
Smith LE. Pathogenesis of retinopathy of prematurity. Semin Neonatol. 2003;8:469–73. https://doi.org/10.1016/s1084-2756(03)00119-2
Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012;367:2515–26. https://doi.org/10.1056/NEJMra1208129
Mintz-Hittner HA, Kennedy KA, Chuang AZ, Group, B-RC. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603–15. https://doi.org/10.1056/NEJMoa1007374
Hard AL, Hellstrom A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment—a review. Acta Paediatr. 2011;100:1523–7. https://doi.org/10.1111/j.1651-2227.2011.02445.x
Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012;153:327–33. https://doi.org/10.1016/j.ajo.2011.07.005. e321
Le Cras TD, Markham NE, Tuder RM, Voelkel NF, Abman SH. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J Physiol Lung Cell Mol Physiol. 2002;283:L555–62. https://doi.org/10.1152/ajplung.00408.2001
Liotta M, Rose PG, Escobar PF. Pulmonary hypertension in two patients treated with bevacizumab for recurrent ovarian cancer. Gynecol Oncol. 2009;115:308–9. https://doi.org/10.1016/j.ygyno.2009.08.003
Doxey S, Radwan A, Nyp MF. Outcomes of infants with severe ROP at risk of treatment with Avastin compared to laser surgery, https://scholarlyexchange.childrensmercy.org/cgi/viewcontent.cgi?article=1195&context=researchdays. 2021.
Abman SH. Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease. Adv Exp Med Biol. 2010;661:323–35. https://doi.org/10.1007/978-1-60761-500-2_21
Abman SH. Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn. Neonatology. 2007;91:283–90.
The authors would like to thank the funding sources. This work was supported in part by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 5 R01 HD072929 09 (SL), Children’s Miracle Network Grant at UC Davis Children’s Hospital (DS).
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplement Table 2: Description of echocardiographic features, respiratory support, and pulmonary vasodilator therapy before and after intravitreal bevacizumab treatment for ROP.
About this article
Cite this article
Park, L., Donohue, L., Lakshminrusimha, S. et al. Intravitreal bevacizumab injection for retinopathy of prematurity and pulmonary hypertension. J Perinatol (2022). https://doi.org/10.1038/s41372-022-01489-0